Tag Archives: moderate to severe rheumatoid arthritis treatment

Roche subcutaneous formulation of RoACTEMRA received European Commission approval for moderate to severe rheumatoid arthritis treatment

Posted on 29, April 2014 by

First anti IL-6 receptor biologic now available for subcutaneous and intravenous administration for both monotherapy and combination therapy Basel, 29-4-2014 — /EuropaWire/ — Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the subcutaneous formulation of RoACTEMRA (tocilizumab) has received approval from … Read the full press release →

Posted in Business, European Union, Healthcare, Pharma & Biotech, Switzerland

Tagged , , , , ,